ArticleCell and tissue research2025
Phenotypic analysis of mice with inactivation of the deubiquitinating enzyme CYLD in adipose tissue.
Article in Cell and tissue research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The cylindromatosis tumor suppressor (CYLD) is a deubiquitinating enzyme that has been implicated in lipid metabolism. More specifically, CYLD has been associated with lipid homeostasis in Drosophila melanogaster, and CYLD deficiency in mammals has been linked to dysregulation of lipid metabolism in the liver. Comprehensive tissue RNA expression analyses have revealed comparable levels of Cyld mRNA expression in the adipose tissue and liver, the organs that, together with skeletal muscle, primarily regulate lipid homeostasis. In the present study, the role of CYLD in mammalian adipose tissue homeostasis and function was investigated, utilizing a relevant conditional mouse model of CYLD inactivation that permits tissue-specific elimination of the catalytic domain of CYLD. Mutant mice displayed reduced weight-gain rate compared to controls when fed a normal or high-fat diet. Histological analysis of crown-like structures (CLS) indicated a reduced inflammatory response in the white adipose tissue of mutants. Our data collectively demonstrate that CYLD plays a pivotal role in regulating key metabolic parameters and modulating inflammatory responses within adipose tissue.
Indexed as
Identifiers
40601063What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.